Navigation Links
NxStage Medical Reports Fourth Quarter and Full Year 2007 Results
Date:2/12/2008

LAWRENCE, Mass., Feb. 12 /PRNewswire-FirstCall/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced its financial results for the fourth quarter and year ended December 31, 2007.

Revenues for the fourth quarter of 2007 were $29.9 million, compared to $7.4 million in the fourth quarter of 2006 and $11.6 million in the third quarter of 2007. Revenues for the fourth quarter of 2007 include revenues from the acquisition of Medisystems Corporation beginning as of October 1, 2007. Revenues in the chronic home dialysis market were $9.3 million for the fourth quarter of 2007, compared to $4.6 million in the fourth quarter of 2006 and $8.3 million in the third quarter of 2007. Revenues in the critical care market for the fourth quarter of 2007 were $4.9 million, compared to $2.7 million in the fourth quarter of 2006 and $3.3 million in the third quarter of 2007. Revenues in the in-center market, from the Company's Medisystems business, were $15.7 million in the fourth quarter of 2007.

Full year 2007 revenues were $60.0 million, including revenues from the Medisystems acquisition in the fourth quarter, a 188% increase compared to $20.8 million for the full year 2006. Full year 2007 revenues in the chronic home dialysis market totaled $29.8 million, a 134% increase compared to $12.7 million for the full year 2006. For the full year 2007, critical care revenues were $14.4 million, a 78% increase compared to $8.1 million for the full year 2006.

At the end of 2007, NxStage was working with 334 dialysis centers to provide home hemodialysis therapy to 2,223 end-stage renal disease (ESRD) patients using the Company's System One(TM) portable dialysis machine. This compares to
'/>"/>

SOURCE NxStage Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. NxStage Medical to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 7, 2008
2. NxStage(R) Medical to Report Fourth Quarter & Full Year 2007 Financial Results on Tuesday, February 12th
3. NxStage Medical Establishes $50 Million Credit Facility with a Group of Lenders Led by Merrill Lynch Capital
4. NxStage Medical Reports Third Quarter 2007 Results
5. NxStage Medical Completes Acquisition of Medisystems
6. Aircraft Medical Files Counter Action Against Verathon
7. NHS Choices Launches Medical News Guide to What Lies Behind the Headlines
8. Symmetry Medical to Provide Fourth Quarter 2007 General Business Update on February 14, 2008
9. Grubb & Ellis Healthcare REIT Acquires Medical Portfolio 1
10. Harnessing Human Energy for Medical Good
11. Pennsylvania Corrections Department to Extend Medical Contract, Save $55 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2009)...rocessing Technology Institute (BTI) have made a n...inhibitory molecule" (FAIM), protects both immune ... death. , Their research is published in the cu... The scientists, Jianxin Huo, Ph.D., and Shengli ...ossibly be manipulated for clinical application an...
(Date:7/2/2009)...USNewswire/ -- Recent news reports have highlighte...ring that physicians meet high standards in their ... Board of Medical Specialties (ABMS), which coordi...forts to develop and implement educational and pro...cation of physician specialists. Certification by...
(Date:7/2/2009)...USNewswire/ -- Pro-life forces won an important ba...o uphold a state law regulating that abortion cent...tering RU-486 (also known as the "abortion pill") ...drug. , , The ruling came in Rogers v. Planne...o a 2004 law requiring that those administering RU...
(Date:7/2/2009)...esses honored in Washington, D.C. , , ARLINGTO...s Health Resources has received the Best Employer...Business Group on Health. , , (Logo: http://... ) , , The award recognizes the nation,s lead...ote a healthy workplace and for helping employees ...
Breaking Medicine News(10 mins):Health News:Gene's novel role may provide key to treating liver and neurodegenerative diseases 2Health News:Seek Out Credentials Before Choosing a Physician - Is Your Cardiologist Board Certified in Cardiovascular Disease? 2Health News:Seek Out Credentials Before Choosing a Physician - Is Your Cardiologist Board Certified in Cardiovascular Disease? 3Health News:Seek Out Credentials Before Choosing a Physician - Is Your Cardiologist Board Certified in Cardiovascular Disease? 4Health News:Ohio Supreme Court Strikes a Blow to Planned Parenthood in Upholding Regulation of 'Abortion Pill' 2Health News:Texas Health Resources Recognized by National Business Group on Health as Leading Employer Promoting Healthy Lifestyles for Employees 2Health News:Texas Health Resources Recognized by National Business Group on Health as Leading Employer Promoting Healthy Lifestyles for Employees 3
...d poisoning in children, The Medical Research Coun...ren’s homes with vivid colors, will do good// to r...evels of lead in paints. Earlier in the year, th...n tested, had portrayed toxic levels of lead in th...
...ly used for a number of painful complaints, have ...d stroke//. This has lead to an order by the Commi...have to carry a warning along with the information...Doctors are being informed of the small but increa...
...e with breast cancer has led to confusion among wo...st cancer//. Cancer Research UK said that most w...to strike the under-70s than women over 70,. Thei...d that 77 per cent of them thought that a woman's ...
...agnosed with polio in spite of receiving 9 doses o...ement, polio can be prevented by 4-10 doses of the...his girl called Jannat. “Earlier she used to roam...stand properly,” Jannat's Mother, Akhbari Khatun s...
Other Medicine News:
(Date:7/3/2009)...nd, July 3 BioCis Pharma Ltd., a p...eadquarters in Turku, Finland,announced positive...oCure(TM),emulsion cream, the company,s novel top...cebo-controlled study, conducted in Finland, inclu...atitis who applied the ProtoCure,emulsion cream t...
(Date:7/1/2009)...Denmark, July 1 A just p...n on Investigational Drugs", Volume,18, Issue 7 2...n,PROSTVAC(TM). This is the most comprehensive an... Quote from the article: "Preliminary clinical tri... II trials have suggested a survival benefit,afte...
(Date:6/30/2009)...30 Calixa Therapeutics Inc. today ...al of CXA-101 in patients with complicated urinary...m, parenteral cephalosporin antibiotic with excell...udomonas aeruginosa , including drug resistant iso...tial treatment for serious bacterial infections in...
(Date:6/29/2009)...ets for Novel Biotherapeutics Based On Naturally R...9 Pangu BioPharma, a subsidiary of...ing of its third patent application on proprietary...ases. Although tRNA synthetases are universal and...ry found in all organisms, human synthetases have ...
Breaking Medicine Technology:BioCis Pharma Reports Positive Phase IIa Clinical Results in Atopic Dermatitis 2New Review on PROSTVAC(TM) Published by Key Investigators From NCI 2Calixa Therapeutics Announces Initiation of Phase 2 Clinical Trial of Its Antibiotic, CXA-101, in Patients with Complicated Urinary Tract Infections 2Pangu BioPharma, aTyr Pharma's Subsidiary in Hong Kong, Files Three Patent Applications 2Pangu BioPharma, aTyr Pharma's Subsidiary in Hong Kong, Files Three Patent Applications 3Nanotechnologists gain powerful new materials probe 10675 1Nanotechnologists gain powerful new materials probe 10675 2ArvinMeritor Proud to Sponsor American Heart Association Campaign 37779 1ArvinMeritor Proud to Sponsor American Heart Association Campaign 37779 2AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31 2008 37774 1AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31 2008 37774 2AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31 2008 37774 3AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31 2008 37774 4AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31 2008 37774 5AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31 2008 37774 6AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31 2008 37774 7AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31 2008 37774 8AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31 2008 37774 9AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31 2008 37774 10AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31 2008 37774 11AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31 2008 37774 12AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31 2008 37774 13AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31 2008 37774 14VVA Introduces Collaboration Between Veterans and Private Sector to Address Healthcare Needs for Vets 37769 1VVA Introduces Collaboration Between Veterans and Private Sector to Address Healthcare Needs for Vets 37769 2
...SINESS WIRE)--Jun 27, 2007 - The University of,Pit...wing study and,press release, "Scientists Culture ...une 15, 2007, Science Daily: "Researchers at,the U...ccessfully,isolated and cultured human hematopoiet...ing that they have found another important,source ...
...Canada and BASEL, Switzerland, June 27 /CNW/ -,Asp...X: ASV) and,Roche today released preliminary resul...ycophenolate mofetil, MMF) to intravenous,cyclopho...are, for,inducing treatment response in the induct...is., Although response rates were similar in both ...
Other Medicine Technology:Bio-Matrix Scientific's Dr. O'Neill Sees University of Pittsburgh's,Published Study on Culture Blood-Forming Stem Cells from Human Fat,Tissue as Supporting Near Term Benefits of Banking Adipose (Fat),Derived Stem Cells 2Bio-Matrix Scientific's Dr. O'Neill Sees University of Pittsburgh's,Published Study on Culture Blood-Forming Stem Cells from Human Fat,Tissue as Supporting Near Term Benefits of Banking Adipose (Fat),Derived Stem Cells 3Aspreva and Roche Announce Preliminary Results for Phase III Study,Evaluating CellCept in Lupus Nephritis 2Aspreva and Roche Announce Preliminary Results for Phase III Study,Evaluating CellCept in Lupus Nephritis 3Aspreva and Roche Announce Preliminary Results for Phase III Study,Evaluating CellCept in Lupus Nephritis 4Aspreva and Roche Announce Preliminary Results for Phase III Study,Evaluating CellCept in Lupus Nephritis 5Aspreva and Roche Announce Preliminary Results for Phase III Study,Evaluating CellCept in Lupus Nephritis 6Aspreva and Roche Announce Preliminary Results for Phase III Study,Evaluating CellCept in Lupus Nephritis 7Aspreva and Roche Announce Preliminary Results for Phase III Study,Evaluating CellCept in Lupus Nephritis 8